Motivation
Risankizumab Safe, Effective in Moderate to Severe Crohn's Disease
MOTIVATE was entirely patients who've been bio-exposed, and, again, it was a prospective, multicenter, placebo-controlled, randomized controlled trial.
MOTIVATE was entirely patients who've been bio-exposed, and, again, it was a prospective, multicenter, placebo-controlled, randomized controlled trial.
/cloudfront-us-east-1.images.arcpublishing.com/gray/W3IBRFDQY5DEDDM4ARDFHWQV7I.jpg)